Currently Enrolling
HIV Trials
Safety, Pharmacokinetics, and Antiviral Activity of GS-6207 Administered Subcutaneously in HIV-1 Infected Adults
GS-US-200-4072 · HIV Trial · Opened 11/14/2018
Major Inclusion/Exclusion Criteria
- HIV Naïve or off ART for > 12 weeks
- Integrase Naive
- HIV RNA > 10,000 but < 400,000 copies
- Absolute CD4 > 200
- GFR > 70
- Willing to start Biktarvy on day 10
- No medications taken within 42 days prior to start of the study drug without prior approval from Sponsor
Safety, Pharmacokinetics, and Antiviral Activity of GS-6207 Administered Subcutaneously in HIV-1 Infected Adults
GS-US-200-4072 · HIV Trial · Opened 11/14/2018
Major Inclusion/Exclusion Criteria
- HIV Naïve or off ART for > 12 weeks
- Integrase Naive
- HIV RNA > 10,000 but < 400,000 copies
- Absolute CD4 > 200
- GFR > 70
- Willing to start Biktarvy on day 10
- No medications taken within 42 days prior to start of the study drug without prior approval from Sponsor
Safety, Pharmacokinetics, and Antiviral Activity of GS-6207 Administered Subcutaneously in HIV-1 Infected Adults
GS-US-200-4072 · HIV Trial · Opened 11/14/2018
Major Inclusion/Exclusion Criteria
- HIV Naïve or off ART for > 12 weeks
- Integrase Naive
- HIV RNA > 10,000 but < 400,000 copies
- Absolute CD4 > 200
- GFR > 70
- Willing to start Biktarvy on day 10
- No medications taken within 42 days prior to start of the study drug without prior approval from Sponsor
HSV Trials
No trials found.
Other Trials
No trials found.